Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    100.0%

    Based on 4 completed trials

    Completion Rate
    100%(4/4)
    Active Trials
    0(0%)
    Results Posted
    50%(2 trials)

    Phase Distribution

    Phase 2
    1
    25%
    Phase 3
    3
    75%

    Phase Distribution

    0

    Early Stage

    1

    Mid Stage

    3

    Late Stage

    Phase Distribution4 total trials
    Phase 2Efficacy & side effects
    1(25.0%)
    Phase 3Large-scale testing
    3(75.0%)

    Highest Phase Reached

    Phase 3

    Trial Status & Enrollment

    Completion Rate

    100.0%

    4 of 4 finished

    Non-Completion Rate

    0.0%

    0 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    4

    all time

    Status Distribution
    Completed(4)

    Detailed Status

    Completed4

    Development Timeline

    Analytics

    Development Status

    Total Trials
    4
    Active
    0
    Success Rate
    100.0%
    Most Advanced
    Phase 3

    Trials by Phase

    Phase 21 (25.0%)
    Phase 33 (75.0%)

    Trials by Status

    completed4100%

    Recent Activity

    0 active trials
    Showing 4 of 4
    completedphase_3

    SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System

    NCT00307047
    completedphase_2

    Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries

    NCT00140101
    completedphase_3

    SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)

    NCT00180479
    completedphase_3

    SPIRIT II: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System

    NCT00180310

    Clinical Trials (4)

    Showing 4 of 4 trials
    NCT00307047Phase 3

    SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System

    Completed
    NCT00140101Phase 2

    Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries

    Completed
    NCT00180479Phase 3

    SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)

    Completed
    NCT00180310Phase 3

    SPIRIT II: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System

    Completed

    All 4 trials loaded

    Drug Details

    Intervention Type
    Device
    Total Trials
    4